Andrew M Dylag

Dr. Andrew M Dylag


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
ADAndrew M Dylag
Andrew M Dylag
JHJeannie Haak
Jeannie Haak
MYMin Yee
Min Yee
MOMichael A. O’rEilly
Michael A. O’rEilly

1 October 2023 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Open access
ADAndrew M Dylag
Andrew M Dylag
RMRavi Misra
Ravi Misra
GBGautam Bandyopadhyay
Gautam Bandyopadhyay
CPCory Poole
Cory Poole
HHHeidie L. Huyck
Heidie L. Huyck
GPGloria Pryhuber
Gloria Pryhuber
We provide new insights into the natural history of bronchopulmonary dysplasia in donor human lungs after the neonatal intensive care unit hospitalization. This study provides new insights into how the proteome and histopathology of BPD changes in early childhood, uncovering novel pathways for future study.

1 August 2020 in The Journal of Pediatrics
Verified
Journal Article
Closed access
ADAndrew M Dylag
Andrew M Dylag
HKHannah G. Kopin
Hannah G. Kopin
MOMichael A. O'REilly
Michael A. O'REilly
HWHongyue Wang
Hongyue Wang
SDStephanie D. Davis
Stephanie D. Davis
GPGloria S. Pryhuber
Gloria S. Pryhuber

15 April 2021 in Children
Verified
Journal Article
Open access
PDF file
ADAndrew M Dylag
Andrew M Dylag
JTJamey Tulloch
Jamey Tulloch
KPKaren E. Paul
Karen E. Paul
JMJeffrey M. Meyers
Jeffrey M. Meyers
Background: Prevention of chronic lung disease (CLD) requires a multidisciplinary approach spanning from the delivery room to Neonatal Intensive Care Unit (NICU) discharge. In 2018, a quality improvement (QI) initiative commenced in a level 4 NICU with the goal of decreasing chronic lung disease rates below the Vermont Oxford Network (VON) average of 24%. Methods: Improvement strategies focused on addressing the primary drivers of ventilation strategies, surfactant administration, non-invasive ventilation, medication use, and nutrition/fluid management. The primary outcome was VON CLD, defined as need for mechanical ventilation and/or supplemental oxygen use at 36 weeks postmenstrual age. Statistical process control charts were used to display and analyze data over time. Results: The overall CLD rate decreased from 33.5 to 16.5% following several interventions, a 51% reduction that has been sustained for >18 months. Changes most attributable to this include implementation of the “golden hour” gestational age (GA) based delivery room protocol that encourages early surfactant administration and timely extubation. Fewer infants were intubated across all GA groups with the largest improvement among infants 26–27 weeks GA. Conclusions: Our efforts significantly decreased CLD through GA-based respiratory guidelines and a comprehensive, rigorous QI approach that can be applicable to other teams focused on improvement.

29 July 2021 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
ADAndrew M Dylag
Andrew M Dylag
JHJeannie Haak
Jeannie Haak
RWRachel Warren
Rachel Warren
MYMin Yee
Min Yee
GPGloria Pryhuber
Gloria Pryhuber
MOMichael A. O’rEilly
Michael A. O’rEilly
It is well known that supplemental oxygen used to treat preterm infants in respiratory distress is associated with permanently disrupting lung development and the host response to influenza A virus (IAV). However, many infants who go home with normally functioning lungs are also at risk for hyperreactivity after a respiratory viral infection. We recently reported a new, low-dose hyperoxia mouse model (40% for 8 days; 40×8) that causes a transient change in lung function that resolves, rendering 40×8 adult animals functionally indistinguishable from room air controls. Here we report that when infected with IAV, 40×8 mice display an early transient activation of TGFβ signaling and later airway hyperreactivity associated with peribronchial inflammation (profibrotic macrophages) and fibrosis compared with infected room air controls, suggesting neonatal oxygen induced hidden molecular changes that prime the lung for hyperreactive airways disease. Although searching for potential activators of TGFβ signaling, we discovered that thrombospondin-1 (TSP-1) is elevated in naïve 40×8 mice compared with controls and localized to lung megakaryocytes and platelets before and during IAV infection. Elevated TSP-1 was also identified in human autopsy samples of former preterm infants with bronchopulmonary dysplasia. These findings reveal how low doses of oxygen that do not durably change lung function may prime it for hyperreactive airways disease by changing expression of genes, such as TSP-1, thus helping to explain why former preterm infants who have normal lung function are susceptible to airway obstruction and increased morbidity after viral infection.

20 June 2024 in Physiological Reports
Verified
Journal Article
Open access
MFMargaret A. T. Freeberg
Margaret A. T. Freeberg
TTThomas H. Thatcher
Thomas H. Thatcher
SCSarah V. Camus
Sarah V. Camus
LHLinghong Huang
Linghong Huang
JAJohn Atkinson
John Atkinson
PSPatricia J. Sime
Patricia J. Sime
Pulmonary fibrosis is an interstitial scarring disease of the lung characterized by poor prognosis and limited treatment options. Tissue transglutaminase 2 (TG2) is believed to promote lung fibrosis by crosslinking extracellular matrix components and activating latent TGFβ. This study assessed physiologic pulmonary function and metabolic alterations in the mouse bleomycin model with TG2 genetic deletion. TG2‐deficient mice demonstrated attenuated the fibrosis and preservation of lung function, with significant reduction in elastance and increases in compliance and inspiratory capacity compared to control mice treated with bleomycin. Bleomycin induced metabolic changes in the mouse lung that were consistent with increased aerobic glycolysis, including increased expression of lactate dehydrogenase A and increased production of lactate, as well as increased glutamine, glutamate, and aspartate. TG2‐deficient mice treated with bleomycin exhibited similar metabolic changes but with reduced magnitude. Our results demonstrate that TG2 is required for a typical fibrosis response to injury. In the absence of TG2, the fibrotic response is biochemically similar to wild‐type, but lesions are smaller and lung function is preserved. We also show for the first time that profibrotic pathways of tissue stiffening and metabolic reprogramming are interconnected, and that metabolic disruptions in fibrosis go beyond glycolysis.